Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 8,116,808 | 14,715,520 | 5,877,177 | 4,761,342 | 4,896,493 |
| Marketable Securities | 215,946 | 4,274,975 | 342,400 | 351,620 | 227,841 |
| Receivables | 8,625,285 | 11,803,820 | 11,476,580 | 11,422,810 | 10,493,280 |
| Inventories | 5,855,652 | 8,054,825 | 7,952,203 | 8,609,852 | 8,848,074 |
| Other current assets | 45,219,339 | 46,960 | 30,260 | 24,817 | 88,062 |
| TOTAL | $68,033,030 | $38,896,100 | $25,678,620 | $25,170,440 | $24,553,750 |
| Non-Current Assets | |||||
| PPE Net | 10,675,520 | 13,369,700 | 13,657,490 | 13,697,990 | 13,741,770 |
| Investments And Advances | 2,183,315 | 2,354,859 | 3,069,223 | 3,894,014 | 4,530,270 |
| Intangibles | 21,691,273 | 55,245,930 | 55,871,690 | 56,290,840 | 55,587,710 |
| Other Non-Current Assets | 9,212,852 | 10,478,101 | 10,497,507 | 9,450,986 | 9,232,470 |
| TOTAL | $43,762,960 | $81,448,590 | $83,095,910 | $83,333,830 | $83,092,220 |
| Total Assets | $111,796,000 | $120,344,700 | $108,774,500 | $108,504,300 | $107,646,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 4,177,048 | 5,504,063 | 4,951,735 | 6,713,864 | 7,046,310 |
| Accounts payable and accrued liabilities | 18,588,930 | 23,584,820 | 24,138,510 | 21,000,650 | 19,942,410 |
| Accrued Expenses | 370,373 | 1,050,629 | 672,424 | 988,671 | 574,496 |
| Other current liabilities | 24,365,490 | 2,436,709 | 2,785,953 | 2,207,619 | 2,331,530 |
| TOTAL | $47,501,840 | $32,576,220 | $32,548,620 | $30,910,800 | $29,894,750 |
| Non-Current Liabilities | |||||
| Long Term Debt | 23,583,310 | 39,215,450 | 28,288,560 | 28,592,870 | 28,573,830 |
| Other Non-Current Liabilities | 11,927,257 | 12,773,931 | 13,455,957 | 13,681,443 | 13,801,876 |
| TOTAL | $35,869,640 | $57,400,860 | $46,878,530 | $47,605,140 | $47,589,500 |
| Total Liabilities | $83,371,480 | $89,977,090 | $79,427,150 | $78,515,950 | $77,484,250 |
| Shareholders' Equity | |||||
| Common Shares | 1,691,158 | 1,807,405 | 1,852,260 | 1,857,378 | 1,882,837 |
| Retained earnings | 12,334,030 | 12,930,930 | 10,923,790 | 10,731,980 | 10,314,370 |
| Other shareholders' equity | 10,081,667 | 11,018,860 | 12,032,125 | 12,848,592 | 13,353,181 |
| TOTAL | $28,424,520 | $30,367,620 | $29,347,380 | $29,988,320 | $30,161,730 |
| Total Liabilities And Equity | $111,796,000 | $120,344,710 | $108,774,530 | $108,504,270 | $107,645,980 |